Provided by Tiger Fintech (Singapore) Pte. Ltd.

Relmada Therapeutics, Inc.

1.60
-0.0500-3.03%
Post-market: 1.600.00000.00%19:53 EDT
Volume:680.37K
Turnover:1.06M
Market Cap:53.11M
PE:-0.73
High:1.68
Open:1.65
Low:1.44
Close:1.65
52wk High:3.98
52wk Low:0.2404
Shares:33.19M
Float Shares:23.27M
Volume Ratio:0.12
T/O Rate:2.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1880
EPS(LYR):-2.6515
ROE:-175.12%
ROA:-95.67%
PB:3.33
PE(LYR):-0.60

Loading ...

Relmada Therapeutics Inc. Announces Availability of Regulation FD Disclosure

Reuters
·
Sep 02

Sergio Traversa, CEO of Relmada Therapeutics Inc., Reports Acquisition of Common Shares

Reuters
·
Aug 29

Relmada Therapeutics Q2 EPS $-0.3

THOMSON REUTERS
·
Aug 08

Relmada Therapeutics Inc - Phase 2 Study for Sepranolone in Prader-Willi Syndrome in 2026

THOMSON REUTERS
·
Aug 08

Relmada Therapeutics Inc - Ndv-01 Phase Iii Trial to Start in 1H 2026

THOMSON REUTERS
·
Aug 08

Relmada Therapeutics Inc - Ndv-01 Shows 91% Response Rate in Bladder Cancer

THOMSON REUTERS
·
Aug 08

Relmada Therapeutics Inc. Faces Nasdaq Listing Challenge Due to Sub-$1 Share Price

Reuters
·
Jul 24

Press Release: Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Dow Jones
·
Jun 17

Relmada Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
May 28

Paul Edward Kelly, COO, Reports Acquisition of Relmada Therapeutics Inc. Common Shares

Reuters
·
May 21

Relmada Therapeutics CFO Maged Shenouda Reports Acquisition of Common Shares

Reuters
·
May 21

CEO Sergio Traversa Acquires Common Shares of Relmada Therapeutics Inc

Reuters
·
May 21

Relmada Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Relmada Therapeutics Inc. Switches Audit Firms Amid Acquisition, No Disagreements Reported

Reuters
·
May 13

BRIEF-Relmada Therapeutics Q1 Net Income USD -17.5 Million

Reuters
·
May 13

Relmada Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Reuters
·
May 10

Relmada Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Reuters
·
May 02